Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension

• Published in: Circulation. Heart failure Vol. 5; no. 1; pp. 97 - 105
• Main Authors: de Man, Frances S, Handoko, M Louis, van Ballegoij, Joris J M, Schalij, Ingrid, Bogaards, Sylvia J P, Postmus, Pieter E, van der Velden, Jolanda, Westerhof, Nico, Paulus, Walter J, Vonk-Noordegraaf, Anton
• Format: Journal Article
• Language: English
• Published: United States 01.01.2012
• Subjects: Adrenergic beta-1 Receptor Antagonists - pharmacology; Adrenergic beta-1 Receptor Antagonists - therapeutic use; Animals; Antihypertensive Agents - pharmacology; Antihypertensive Agents - therapeutic use; Bisoprolol - pharmacology; Bisoprolol - therapeutic use; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Echocardiography; Fibrosis; Heart Failure - diagnostic imaging; Heart Failure - etiology; Heart Failure - prevention & control; Heart Ventricles - diagnostic imaging; Heart Ventricles - pathology; Heart Ventricles - physiopathology; Hypertension, Pulmonary - chemically induced; Hypertension, Pulmonary - complications; Hypertension, Pulmonary - drug therapy; Male; Monocrotaline - adverse effects; Rats; Rats, Wistar; Signal Transduction - drug effects; Signal Transduction - physiology; Vascular Resistance - drug effects; Vascular Resistance - physiology

In pulmonary arterial hypertension (PH), sympathetic adrenergic activity is highly elevated. Sympathetic overactivity is a compensatory mechanism at first, but might be detrimental for cardiac function in the long run. We therefore investigated whether chronic low-dose treatment with bisoprolol (a c...